Sulzer Medica shares touch low for the year:
This article was originally published in Clinica
Executive Summary
While Sulzer Medica has discounted the potential for financial liability following the admission last year of contamination in the Inter-Op acetabular shell, its share price has fallen. The Swiss company says that the costs of the recall are insured and that joint prostheses sales are actually up, year on year. However, its share price reached SFr336 ($204) last week, before recovering to SFr348.